sinusitis/nausea

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 127 rezilta yo

Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis. METHODS TeqCES was an open-label, multicenter, noncomparative study of the safety and efficacy of gatifloxacin. More than 11,000 adult patients with acute uncomplicated rhinosinusitis received

Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by sinus puncture.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To evaluate the efficacy and safety of sparfloxacin in the treatment of patients with acute bacterial maxillary sinusitis, the microbiologic etiology of which was determined by maxillary sinus puncture. METHODS Two hundred fifty-three patients enrolled in the open, noncomparative trial

Pattern of intracranial complications of sinusitis in komfo anokye teaching hospital.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Patients with intracranial complications of sinusitis present a major challenge to all, physicians, otorhinolaryngologists and neurosurgeons, because the purulent collection can be in areas that are not easily accessible like the interhemispheric and subfrontal areas of the brain and

[Epidural abscess secondary to sinusitis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Approximately 0.5-2% of upper viral infections are com-licated by secondary acute bacterial sinusitis and may in rare cases evolve into more serious complications such as meningitis and intracranial abscess. Symptoms are often subtle and nonspecific as fever, headache, scalp tenderness, nausea and

Standardized retrieval of side effects data for meta-analysis of safety outcomes. A feasibility study in acute sinusitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Accurate and complete safety data are indispensable for the proper evaluation of the benefit-to-harm ratio of medical interventions. We evaluated whether a systematic review and meta-analysis of standardized safety data is feasible by requesting information on side effects directly from the

Low-dose macrolides for treating pediatric rhinosinusitis: A retrospective study and literature review

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The effects of low-dose macrolide (LDM) therapy on pediatric chronic rhinosinusitis (CRS) patients are unknown. This study aimed to assess the effectiveness of LDM for treating pediatric refractory CRS. A retrospective study was conducted by a medical chart review. Pediatric CRS patients (age <15

Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Garenoxacin is a des-F(6)-quinolone with in vitro activity against key respiratory pathogens, including Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. Limited data are available regarding the effect of garenoxacin in the treatment of

Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Penicillin-resistant Streptococcus pneumoniae (PRSP) has become a relatively common pathogen in upper and lower respiratory tract infections, including acute bacterial sinusitis (ABS). OBJECTIVE The goal of this analysis was to assess the efficacy and tolerability of moxifloxacin in the

Multicenter comparative trial of ciprofloxacin versus cefuroxime axetil in the treatment of acute rhinosinusitis in a primary care setting. Rhinosinusitis Investigation Group.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In a primary care setting, the efficacy and safety of ciprofloxacin (CIP) 500 mg b.i.d. were compared with those of cefuroxime axetil (CA) 250 mg b.i.d., each given for 10 days, in a nationwide, open, prospective, randomized trial of 1414 adults with acute sinusitis. Patients were enrolled if they

Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In this multicentre, multinational, comparative, double-blind clinical trial, outpatients with both clinical signs and symptoms and radiographic evidence of acute sinusitis were randomly assigned to receive for 7 days either a twice-daily oral regimen of faropenem daloxate (300 mg) or a twice daily

An open label, randomized comparative study of levofloxacin and amoxicillin/clavulanic acid in the treatment of purulent sinusitis in adult Thai patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The objective of the study was to compare the clinical efficacy and bacteriological response of levofloxacin and amoxicillin/clavulanic acid (co-amoxiclav) in the treatment of purulent maxillary sinusitis. Sixty patients randomly received either levofloxacin 300 mg orally once daily (LEV group) or

A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Treatment guidelines for acute bacterial sinusitis recommend 10 to 14 days of therapy with amoxicillin/clavulanate, high-dose amoxicillin, cefpodoxime, cefuroxime, or a newer fluoroquinolone. OBJECTIVE This study compared the clinical efficacy of short-course (5-day) gatifloxacin with

An open multicenter study of the use of gatifloxacin for the treatment of non-complicated acute bacterial rhinosinusitis in adults.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The bacteriological and clinical efficacy and the safety of gatifloxacin for the treatment of non-complicated acute rhinosinusitis was evaluated in 49 adult patients in an open-label multicenter study in Brazil. Patients under age 18, or with associated systemic diseases, were excluded. Diagnosis

Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In this comparative trial, outpatients with acute sinusitis were randomly assigned to receive levofloxacin (500 mg orally once daily) or amoxicillin-clavulanate (500/125 mg orally 3 times daily) for 10 to 14 days. The success rates (cured and improved) 2 to 5 days after the end of treatment were

A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Telithromycin, a new ketolide, exhibits potent activity against respiratory pathogens, including resistant strains. METHODS Five days of telithromycin (800 mg once daily) was compared with 10 days of cefuroxime axetil (250 mg twice daily) in subjects (n = 593) with acute bacterial

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye